Agenus (AGEN)
(Delayed Data from NSDQ)
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Agenus (AGEN) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
by Zacks Equity Research
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.
Agenus (AGEN) Surges: Stock Moves 9.4% Higher
by Zacks Equity Research
Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
by Zacks Equity Research
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
Why Is Agenus (AGEN) Up 11.6% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -16.00% and 18.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celyad (CYAD) Jumps: Stock Rises 6.8%
by Zacks Equity Research
Celyad (CYAD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Agenus Receives Milestone Payment of $5 Million from Incyte
by Zacks Equity Research
Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.
Implied Volatility Surging for Agenus (AGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Agenus (AGEN) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN).